Recursion Pharmaceuticals Inc
$ 3.00
-1.32%
31 Jul - close price
- Market Cap 1,592,287,000 USD
- Current Price $ 3.00
- High / Low $ 3.10 / 2.95
- Stock P/E N/A
- Book Value 1.93
- EPS -1.16
- Next Earning Report 2026-08-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.28 %
- ROE -0.57 %
- 52 Week High 7.18
- 52 Week Low 2.77
About
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that decodes biology by integrating technological innovations in biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company is headquartered in Salt Lake City, Utah.
Analyst Target Price
$7.25
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-06 | 2026-02-25 | 2025-11-05 | 2025-08-05 | 2025-05-05 | 2025-02-28 | 2024-11-06 | 2024-08-08 | 2024-05-09 | 2024-02-27 | 2023-11-09 | 2023-08-08 |
| Reported EPS | -0.22 | -0.21 | -0.36 | -0.41 | -0.5 | -0.53 | -0.34 | -0.4 | -0.39 | -0.42 | -0.43 | -0.38 |
| Estimated EPS | -0.26 | -0.3 | -0.38 | -0.35 | -0.52 | -0.4168 | -0.33 | -0.38 | -0.43 | -0.45 | -0.39 | -0.37 |
| Surprise | 0.04 | 0.09 | 0.02 | -0.06 | 0.02 | -0.1132 | -0.01 | -0.02 | 0.04 | 0.03 | -0.04 | -0.01 |
| Surprise Percentage | 15.3846% | 30% | 5.2632% | -17.1429% | 3.8462% | -27.1593% | -3.0303% | -5.2632% | 9.3023% | 6.6667% | -10.2564% | -2.7027% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-05 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.25 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: RXRX
2026-07-31 14:43:00
Vanguard Capital Management LLC and its affiliates have disclosed a beneficial ownership of 26,744,129 shares, representing a 5.09% stake, in Recursion Pharmaceuticals Inc. (RXRX) as of June 30, 2026. This Schedule 13G filing indicates Vanguard has sole voting power over 3,978,189 shares and sole dispositive power over all 26,744,129 shares. The disclosure clarifies that no other single person has an interest exceeding 5% through Vanguard's holdings.
2026-07-31 03:41:28
An insider at Recursion Pharmaceuticals, Inc. (RXRX) has filed a Rule 144 notice to sell 75,000 Class A shares through Fidelity Brokerage Services LLC, valued at approximately $225,000. These shares were acquired as Founder Shares for compensation on April 20, 2021. The filing also details numerous previous Class A share sales by Christopher C. Gibson and affiliated entities from May to July 2026.
2026-07-30 15:14:09
BlackRock, Inc. has filed an amended Schedule 13G disclosing an 8.5% passive ownership stake in Recursion Pharmaceuticals, Inc.'s Class A shares. This amounts to 44,541,605 shares, with BlackRock holding sole voting power over 43,812,201 shares and sole dispositive power over all 44,541,605 shares. The filing indicates that no single underlying client or investor holds more than five percent of the outstanding common shares.
2026-07-30 03:39:24
A shareholder of Recursion Pharmaceuticals, Inc. (RXRX), associated with Christopher C. Gibson, has filed a Form 144 to sell 50,000 Class A shares valued at over $151,000. These shares are identified as Founders Shares initially acquired as compensation in April 2021. The filing also details numerous previous sales of Class A shares by Gibson and related entities over the past three months.
2026-07-29 15:14:09
Recursion Pharmaceuticals, Inc. (BMV:RXRX) generated 1.34 billion Mexican Pesos in revenue last year. The majority of this revenue, 1.35 billion MXN, came from its Drug Discovery segment. The United States was the largest geographical contributor, accounting for 709.28 million MXN of the company's revenue.
2026-07-27 20:10:25
Christopher C. Gibson, an insider at RXRX, plans to sell 50,000 Class A shares of Recursion Pharmaceuticals (RXRX) via Fidelity Brokerage Services LLC on NASDAQ, valued at approximately $152,702.73. These shares were originally acquired as founder's compensation in 2021. The filing also details numerous prior Class A share sales by Gibson and related entities, including the Gibson Family Trust and Lahwran-3 LLC, over the past three months, with significant aggregate proceeds.
